Suppression of breast cancer: modulation of estrogen receptor and downregulation of gene expression using natural products.

Breast cancer anti-estrogenic estrogen receptor gene expression phytoestrogens

Journal

Natural product research
ISSN: 1478-6427
Titre abrégé: Nat Prod Res
Pays: England
ID NLM: 101167924

Informations de publication

Date de publication:
10 Jul 2023
Historique:
medline: 10 7 2023
pubmed: 10 7 2023
entrez: 10 7 2023
Statut: aheadofprint

Résumé

The main cause of cancer death among women is breast cancer. The most common type of breast cancer is the estrogen receptor positive breast cancer. Discovery of estrogen receptor provided a highly effective target for treatment of hormone-dependent breast cancer. Selective estrogen receptor inhibitors are useful for halting the growth of breast cancer cells and inducing apoptosis. Tamoxifen, a popular selective estrogen receptor modulator, can treat breast cancer but also has unfavourable side effects due to its estrogenic activity in other tissues. Many herbal remedies and bioactive natural compounds, such as genistein, resveratrol, ursolic acid, betulinic acid, epigallocatechin-3-gallate, prenylated isoflavonoids, zearalenol, coumestrol, pelargonidin, delphinidin, and biochanin A, have the ability to specifically modulate the estrogen receptor alpha. Moreover, several of these compounds speed up cell death by supressing estrogen receptor gene expression. This opens wide avenue to introduce number of natural medicines with a revolutionary therapeutic impact and few side effects.

Identifiants

pubmed: 37427947
doi: 10.1080/14786419.2023.2232926
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Auteurs

Haidy Ahmed (H)

Pharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.

Alyaa Abdelraheem (A)

Pharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.

Mona Salem (M)

Pharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.

Martha Sabry (M)

Pharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.

Nada Fekry (N)

Pharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.

Fatma Mohamed (F)

Pharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.

Ahmed Saber (A)

Pharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.

Diletta Piatti (D)

School of Pharmacy, University of Camerino, Camerino, Italy.

Miral Sabry (M)

Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

Omar Sabry (O)

Pharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.
Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

Giovanni Caprioli (G)

School of Pharmacy, University of Camerino, Camerino, Italy.

Classifications MeSH